A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC

被引：0
|
作者：
Li, J. [1 ]
机构：
[1] Sichuan Prov Canc Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
stage III nonsmall cell lung cancer; neoadjuvant immunotherapy; low dose radiation therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P29.07
引用
收藏
页码：S1049 / S1050
页数：2
相关论文
共 50 条
  • [41] Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
    Yan, S.
    Wang, J.
    Liu, B.
    Yang, X.
    Lyu, C.
    Li, S.
    Wang, Y.
    Bi, J.
    Li, X.
    Tao, Y.
    Chen, J.
    Yang, Y.
    Wu, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S733 - S733
  • [42] Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial
    Nystrom, ML
    Steele, JPC
    Shamash, J
    Neville, F
    Oliver, RTD
    MELANOMA RESEARCH, 2003, 13 (02) : 197 - 199
  • [43] Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
    Garassino, Marina C.
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Bischoff, Helge
    Reinmuth, Niels
    Cove-Smith, Laura
    Mansy, Talal
    Cortinovis, Diego
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1415 - 1427
  • [44] Updated event-free survival of neoadjuvant toripalimab with chemotherapy for resectable stage III NSCLC (NeoTAP01 study)
    Zhao, Z-R.
    Long, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S984 - S984
  • [45] Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
    Faivre-Finn, C.
    Vicente, D.
    Kurata, T.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Spigel, D. R.
    Garassino, M. C.
    Reck, M.
    Senan, S.
    Naidoo, J.
    Rimner, A.
    Wu, Y-L.
    Gray, J. E.
    Ozguroglu, M.
    Lee, K. H.
    Newton, M.
    Wang, L.
    Thiyagarajah, P.
    Antonia, S. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1178 - S1179
  • [46] Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
    Leonetti, A.
    Minari, R.
    Boni, L.
    Gnetti, L.
    Bordi, P.
    Verze, M.
    Ampollini, L.
    Gelsomino, F.
    Toschi, L.
    Cecere, F.
    Pilotto, S.
    Metro, G.
    Passiglia, F.
    Cortinovis, D.
    Guaitoli, G.
    Pasello, G.
    Delmonte, A.
    Mazzoni, F.
    Bria, E.
    Galetta, D.
    Genova, C.
    Rocco, D.
    Parra, H. Soto
    Bearz, A.
    Migliorino, M. R.
    Camerini, A.
    Tognetto, M.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S231 - S231
  • [47] Comparison of Radiation Dose of Induction Chemoradiation Therapy Followed by Surgery for Potentially Resectable Stage III Non-Small Cell Lung Cancer
    Takehana, K.
    Inokuchi, H.
    Tsutsui, K.
    Hiraoka, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 233 - 234
  • [48] PACIFIC-6: A Phase II Study of Durvalumab after sequential Radiochemotherapy in Patients with Stage III non-resectable NSCLC
    Reck, M.
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    Wehler, T.
    PNEUMOLOGIE, 2020, 74 : S37 - S37
  • [49] Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
    Zhu, X.
    Sun, L.
    Song, N.
    Sun, F.
    Yang, J.
    Duan, L.
    Zhao, D.
    He, W.
    Luo, J.
    Zhang, H.
    Wu, C.
    Zhu, Y.
    Zhang, P.
    Jiang, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S942 - S942
  • [50] CONCORDE: A Multicentre Phase Ib Trial of DNA Damage Response Inhibitors and Durvalumab Consolidation in Patients with Unresectable Stage IIB/III NSCLC Undergoing Radiotherapy: The Newcastle experience
    Greystoke, Alastair
    Hassani, Adam
    Philip, Rachel
    Pickles, Rebecca
    Smith, Eleanor
    Turnbull, Helen
    Willis, Nick
    Stamp, Alexander
    Sellars, Sharon
    Kendall, Jessica
    Oughton, Jamie
    Brown, Sarah
    Walker, Fiona
    Franks, Kevin
    Harrow, Stephen
    Shaw, Paul
    Walls, Gerard
    Hiley, Crispin
    Ojo, Oluwaseun
    Rizos, Konstantinos
    Chalmers, Anthony
    Faivre-Finn, Corinne
    LUNG CANCER, 2025, 200
12345